



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & TWELVE MONTHS ENDED 31st MARCH ' 2022.

Rs. In Lakhs

| PART - I | | STANDALONE | | | | |
|----------|---|-----------------------|------------------|------------------|--------------------|--------------------|
| Sl. No. | PARTICULARS | For the Quarter Ended | | | For the Year Ended | |
| | | 31/03/2022 | 31/12/2021 | 31/03/2021 | 31/03/2022 | 31/03/2021 |
| | | UN-AUDITED | UN-AUDITED | UN-AUDITED | AUDITED | AUDITED |
| | | (1) | (2) | (3) | (4) | (5) |
| 1 | Income | | | | | |
| | Revenue from operations | 36,384.72 | 39,158.53 | 25,916.48 | 1,32,022.21 | 1,00,971.85 |
| | Other Income | 13,439.58 | 927.43 | 329.82 | 18,778.80 | 1,423.70 |
| | Total income | 49,824.30 | 40,085.96 | 26,246.30 | 1,50,801.01 | 1,02,395.55 |
| 2 | Expenses | | | | | |
| | a) Cost of materials consumed | 13,027.81 | 11,847.97 | 8,737.46 | 45,945.64 | 31,031.50 |
| | b) Purchases of stock-in-trade | - | - | - | - | - |
| | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,994.03) | 96.07 | 398.28 | (6,035.21) | (837.30) |
| | d) Employee benefits expense | 3,112.20 | 2,500.87 | 1,651.27 | 10,048.39 | 7,623.30 |
| | e) R & D expense | 214.42 | 218.85 | 150.63 | 1,035.45 | 1,105.75 |
| | f) Finance costs | 218.87 | 74.17 | 187.03 | 623.10 | 914.37 |
| | g) Depreciation and amortisation expenses | 1,042.08 | 1,050.60 | 831.47 | 3,909.71 | 3,163.58 |
| | h) Manufacturing Expenses | 4,434.34 | 4,625.81 | 4,468.31 | 17,318.86 | 13,378.94 |
| | i) Other Expenses | 1,833.11 | 1,266.16 | 1,141.26 | 5,710.25 | 4,617.49 |
| | Total expenses | 21,888.80 | 21,680.50 | 17,565.71 | 78,556.19 | 60,997.63 |
| 3 | Profit before exceptional items & Tax (1-2) | 27,935.50 | 18,405.46 | 8,680.59 | 72,244.82 | 41,397.92 |
| 4 | Exceptional Items | - | - | - | - | - |
| 5 | Profit before Tax (3-4) | 27,935.50 | 18,405.46 | 8,680.59 | 72,244.82 | 41,397.92 |
| 6 | Tax Expenses | | | | | |
| | a) Current tax | 5,148.01 | 4,620.66 | 1,834.65 | 15,763.03 | 10,171.51 |
| | b) Deferred tax | 341.02 | 85.27 | 400.73 | 671.91 | 361.72 |
| 7 | Net Profit/ (Loss) for the period/year(5-6) | 22,446.47 | 13,699.53 | 6,445.21 | 55,809.88 | 30,864.69 |
| 8 | Other Comprehensive Income | | | | | |
| 8.a | (i) Items that will not be reclassified to profit or loss | (18.06) | (27.95) | (29.87) | (101.95) | (111.85) |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | 4.55 | 7.03 | 7.52 | 25.66 | 28.15 |
| 8.b | (i) Items that will be reclassified to profit or loss | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - |
| | Total other Comprehensive Income | (13.51) | (20.92) | (22.35) | (76.29) | (83.70) |
| 9 | Total Comprehensive Income for the period (7+8) | 22,432.96 | 13,678.61 | 6,422.86 | 55,733.59 | 30,780.99 |
| 10 | Paid-up equity share capital | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 |
| | Face Value of the Share | Re.1.00 | Re.1.00 | Re.1.00 | Re.1.00 | Re.1.00 |
| 11 | Other Equity | - | - | - | 1,49,523.67 | 1,03,972.68 |
| 12 | Earning Per Share (EPS)-Face value of Rs.1/- each) | | | | | |
| | a) Basic | 8.82 | 5.38 | 2.53 | 21.92 | 12.12 |
| | b) Diluted | 8.82 | 5.38 | 2.53 | 21.92 | 12.12 |
| | | (not annualised) | (not annualised) | (not annualised) | (annualised) | (annualised) |

| PART - II | | CONSOLIDATED | | | | |
|-----------|---|-----------------------|------------------|------------------|--------------------|--------------------|
| Sl. No. | PARTICULARS | For the Quarter Ended | | | For the Year Ended | |
| | | 31/03/2022 | 31/12/2021 | 31/03/2021 | 31/03/2022 | 31/03/2021 |
| | | UN-AUDITED | UN-AUDITED | UN-AUDITED | AUDITED | AUDITED |
| | | (1) | (2) | (3) | (4) | (5) |
| 1 | Income | | | | | |
| | Revenue from operations | 36,384.72 | 39,158.53 | 25,916.48 | 1,32,022.21 | 1,00,971.85 |
| | Other Income | 1,687.12 | 6,468.51 | 329.82 | 9,238.03 | 1,423.70 |
| | Total income | 38,071.84 | 45,627.04 | 26,246.30 | 1,41,260.24 | 1,02,395.55 |
| 2 | Expenses | | | | | |
| | a) Cost of materials consumed | 13,027.81 | 11,847.97 | 8,737.46 | 45,945.64 | 31,031.50 |
| | b) Purchases of stock-in-trade | - | - | - | - | - |
| | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,994.03) | 96.07 | 398.28 | (6,035.21) | (837.30) |
| | d) Employee benefits expense | 3,112.20 | 2,500.87 | 1,651.27 | 10,048.39 | 7,623.30 |
| | e) R & D expense | 214.42 | 218.85 | 150.63 | 1,035.45 | 1,105.75 |
| | f) Finance costs | 218.87 | 74.17 | 187.03 | 623.10 | 914.37 |
| | g) Depreciation and amortisation expense | 1,042.08 | 1,050.60 | 831.47 | 3,909.71 | 3,163.58 |
| | h) Manufacturing Expenses | 4,434.34 | 4,625.81 | 4,468.31 | 17,318.86 | 13,378.94 |
| | i) Other Expenses | 1,887.94 | 1,266.91 | 1,141.48 | 5,766.55 | 4,621.60 |
| | Total expenses | 21,943.63 | 21,681.25 | 17,565.93 | 78,612.49 | 61,001.74 |
| 3 | Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2) | 16,128.21 | 23,945.79 | 8,680.37 | 62,647.75 | 41,393.81 |
| 4 | Add : Share of profit/(Loss) of Associates. | - | - | 1,866.60 | 4,111.23 | 5,373.60 |
| 5 | Profit before exceptional items , Tax (3+4) | 16,128.21 | 23,945.79 | 10,546.97 | 66,758.98 | 46,767.41 |
| 6 | Exceptional Items | - | - | - | - | - |
| 7 | Profit before Tax (5-6) | 16,128.21 | 23,945.79 | 10,546.97 | 66,758.98 | 46,767.41 |
| 8 | Tax Expenses | | | | | |
| | a) Current tax | 5,964.54 | 6,843.36 | 1,834.65 | 19,040.47 | 10,171.51 |
| | b) Deferred tax | 996.87 | 1,095.53 | 400.73 | 2,338.02 | 361.72 |
| 9 | Net Profit/ (Loss) for the period/year(7-8) | 9,166.80 | 16,006.90 | 8,311.59 | 45,380.49 | 36,234.18 |
| 10 | Other Comprehensive Income | | | | | |
| 10.a | (i) Items that will not be reclassified to profit or loss | (18.06) | (27.95) | (29.87) | (101.95) | (111.85) |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | 4.55 | 7.03 | 7.52 | 25.66 | 28.15 |
| 10.b | (i) Items that will be reclassified to profit or loss | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - |
| | Total other Comprehensive Income | (13.51) | (20.92) | (22.35) | (76.29) | (83.70) |
| 11 | Total Comprehensive Income for the period (9 + 10) | 9,153.29 | 15,985.98 | 8,289.24 | 45,304.20 | 36,150.48 |
| 12 | Paid-up equity share capital | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 |
| | Face Value of the Share | Re.1.00 | Re.1.00 | Re.1.00 | Re.1.00 | Re.1.00 |
| 13 | Other Equity | - | - | - | 1,50,172.39 | 1,15,535.18 |
| 14 | Earning Per Share (EPS)- (Face value of Rs.1/- each) | | | | | |
| | a) Basic - | 3.60 | 6.29 | 3.27 | 17.83 | 14.23 |
| | b) Diluted | 3.60 | 6.29 | 3.27 | 17.83 | 14.23 |
| | | (not annualised) | (not annualised) | (not annualised) | (annualised) | (annualised) |

- Notes**
- 1)** The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9 May,2022 . The above results for the year ended 31st March 2022 has been audited and for the quarter ended 31st Mar2022 has been reviewed by the statutory auditors of the company
 - 2)** The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3)** The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma,Inc.,USA.
 - 4)** The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5)** The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary , Suven Pharma , Inc., USA. Apart from the above the shortage or non- availability of vessels leading to delay in shipments , increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profiability.
 - 6)** The other Income (Standalone figures) for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q3 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs pertaining to Gain on Investments on part disinvestment of Capital from our Subsidiary, Suven pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such Dividend by our subsidiary.
 - 7)** The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13 th Dec,2021. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P. w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar'2022.
 - 8)** The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 1.00 per equity share (100% of Face value of Rs.1.00), totaling to Rs. 2.00 per equity share (200% of Face value of Rs. 1.00 each) for the financial year 2021-22.
 - 9)** The corresponding previous period figures have been regrouped/reclassified where ever necessary.
 - 10)** Post approval of the Board in the meeting held on 5 April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt. Ltd. an SEZ company engaged in formulations business for USD 20.50 Mn and has become a wholly owned subsidiary of the Company w.e.f. 22 April 2022.

For SUVEN PHARMACEUTICALS LTD

Place : Hyderabad
Date : 9th May ' 2022

VENKAT JASTI
Managing Director
DIN: 00278028



SUVEN PHARMACEUTICALS LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities

Rs.in Lakhs

| Particulars | Standalone as at | | Consolidated as at | |
|---|--------------------|--------------------|--------------------|--------------------|
| | 31/03/2022 | 31/03/2021 | 31/03/2022 | 31/03/2021 |
| A ASSETS | Audited | Audited | Audited | Audited |
| 1 Non-current assets | | | | |
| (a) Property, Plant and Equipment | 53,055.18 | 43,706.51 | 53,055.18 | 43,706.51 |
| (b) Capital Work-in-Progress | 2,999.38 | 9,614.91 | 2,999.38 | 9,614.91 |
| (c) Other Intangible Assets | 223.64 | 241.75 | 223.64 | 241.75 |
| (d) Intangible assets under development | - | 17.30 | - | 17.30 |
| (e) Right of use of assets | 140.56 | 167.53 | 140.56 | 167.53 |
| (f) Financial Assets | | | | |
| I. Investments | 11,867.29 | 24,564.73 | 11,709.67 | 36,119.40 |
| II. Loans | 6.95 | 6.20 | 6.95 | 6.20 |
| III. Other Financial Assets | 539.21 | 495.18 | 1,269.59 | 495.18 |
| (g) Deferred tax assets (net) | - | - | - | - |
| (h) Other non current assets | 760.56 | 599.21 | 760.56 | 599.21 |
| Total Non-Current assets | 69,592.77 | 79,413.32 | 70,165.53 | 90,967.99 |
| 2 Current assets | | | | |
| (a) Inventories | 28,341.73 | 20,108.04 | 28,341.73 | 20,108.04 |
| (b) Financial Assets | | | - | |
| I. Investments | 48,122.24 | 18,059.38 | 48,122.24 | 18,059.38 |
| II. Trade Receivables | 23,637.23 | 10,238.22 | 23,637.23 | 10,238.22 |
| III. Cash and Cash equivalents | 3,021.05 | 709.14 | 4,456.38 | 718.22 |
| IV. Bank balances otherthan (III) above | 274.20 | 247.10 | 274.20 | 247.10 |
| V. Loans | 18.63 | 21.78 | 18.63 | 21.78 |
| VI. Other Financial assets | - | - | - | - |
| (c) Current Tax asset(net) | - | 224.67 | - | 224.67 |
| (d) Other current assets | 7,480.94 | 6,861.11 | 7,942.79 | 6,861.11 |
| Total Current assets | 1,10,896.02 | 56,469.44 | 1,12,793.20 | 56,478.52 |
| TOTAL - ASSETS | 1,80,488.79 | 1,35,882.76 | 1,82,958.73 | 1,47,446.51 |
| B EQUITY AND LIABILITIES | | | | |
| 1 EQUITY | | | | |
| (a) Equity Share Capital | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 |
| (b) Other Equity | 1,49,523.67 | 1,03,972.68 | 1,50,172.39 | 1,15,535.18 |
| Equity attributable to owners of the company | 1,52,069.32 | 1,06,518.33 | 1,52,718.04 | 1,18,080.83 |
| 2 LIABILITIES | | | | |
| (a) Financial Liabilities | | | | |
| I. Lease Liability | 46.29 | 73.90 | 46.29 | 73.90 |
| II. Borrowings | 2,844.04 | 3,559.09 | 2,844.04 | 3,559.09 |
| (b) Provisions | 889.45 | 664.60 | 889.45 | 664.60 |
| (c) Deferred tax Liabilities (net) | 3,739.55 | 3,093.29 | 5,431.51 | 3,093.29 |
| (d) Other non current liabilities | - | - | - | - |
| Total non-current liabilities | 7,519.33 | 7,390.88 | 9,211.29 | 7,390.88 |
| Current liabilities | | | | |
| (a) Financial Liabilities | | | | |
| I. Lease Liability | 109.09 | 106.82 | 109.09 | 106.82 |
| II. Borrowings | 6,713.31 | 10,563.76 | 6,713.31 | 10,563.76 |
| III. Trade payables | | | - | |
| a) To Micro & Small Enterprises | 200.20 | 996.25 | 200.20 | 996.25 |
| b) Other than Micro & Small Enterprises | 10,389.85 | 7,296.89 | 10,389.85 | 7,296.89 |
| IV. Other Financial Liabilities | 2,126.01 | 2,522.75 | 2,255.27 | 2,524.00 |
| (b) Current Tax liabilities (Net) | 364.22 | - | 364.22 | - |
| (c) Provision Employee benefits | 407.53 | 260.72 | 407.53 | 260.72 |
| (d) Other Current liabilities | 589.93 | 226.36 | 589.93 | 226.36 |
| Total Current liabilities | 20,900.14 | 21,973.55 | 21,029.40 | 21,974.80 |
| Total Liabilities | 28,419.47 | 29,364.43 | 30,240.69 | 29,365.68 |
| TOTAL - EQUITY AND LIABILITIES | 1,80,488.79 | 1,35,882.76 | 1,82,958.73 | 1,47,446.51 |

For Suven pharmaceuticals Ltd

Place : Hyderabad

Date: 9th May, 2022

Venkat Jasti
Managing Director

| SUVEN PHARMACEUTICALS LIMITED | | | |
|---|----------------|---|---|
| Standalone Statement of Cash flows for the period ended 31st March, 2022 | | | |
| (All amounts in Indian Rupees In Lakhs, unless otherwise stated) | | | |
| Particulars | | For the year ended 31st March 2022 | For the year ended 31st March 2021 |
| A. Cash flow from operating activities | | | |
| Profit before tax | | 72,244.82 | 41,397.92 |
| Adjustments : | | | |
| Depreciation and amortisation expense | | 3,825.50 | 3,122.07 |
| Interest Income | | (6.86) | (26.79) |
| Finance Cost | | 623.10 | 914.37 |
| Gain on sale of Current Investment | | (820.31) | (332.77) |
| Dividend received from WOS | | (15,081.85) | - |
| Debit balances writtenoff | | - | 72.16 |
| Effects of foreign exchange rates (Unrealized) | | 442.01 | (97.56) |
| Loss/(Profit) on disposal of Property,plant & equipment | | (0.06) | (3.36) |
| Operating profit before working capital changes | | 61,226.35 | 45,046.06 |
| Adjustments for (Increase)/decrease in operating assets | | | |
| Trade Receivables | | (13,608.80) | 1,336.08 |
| Inventories | | (8,233.69) | (2,620.82) |
| Other non current assets | | 26.97 | (78.95) |
| Other current assets | | (621.56) | (1,269.92) |
| Adjustments for Increase/(decrease) in operating liabilities | | | |
| Trade Payables | | 2,320.35 | 1,194.52 |
| Long term provisions | | 224.85 | (166.86) |
| Short term provision | | 44.86 | (102.78) |
| Other financial liabilities | | 420.66 | 654.28 |
| Other current liabilities | | 363.60 | (164.48) |
| Cash generated from operating activities | | 42,163.59 | 43,827.12 |
| Income taxes paid (net of refunds) | | (15,174.14) | (10,943.58) |
| Net Cash flows from operating activities | (A) | 26,989.45 | 32,883.54 |
| B. Cash flow from Investing activities | | | |
| Payments for Purchase of property, plant and equipment | | (7,518.67) | (11,084.60) |
| Proceeds from sale of Property, plant & equipment | | 0.06 | 3.36 |
| Changes in Investments | | 12,697.44 | - |
| Dividend received from WOS | | 15,081.85 | - |
| Fixed deposits/margin money-placed/matured | | (44.03) | (20.31) |
| Sale/(purchase) of mutual funds | | (29,242.55) | (14,659.28) |
| Bank balances not considered as cash and cash equivalents | | (10.47) | (5.12) |
| Net cash flow from /(used in) investing activities | (B) | (9,036.37) | (25,765.95) |
| C. Cash flows from financing activities | | | |
| (Repayment)/Proceeds from long term borrowings | | (959.73) | (5,472.65) |
| (Repayment)/Proceeds from short term borrowings | | (3,859.71) | 1,230.17 |
| Other non current financial assets | | (0.75) | (0.20) |
| Other current financial assets | | 3.15 | (1.39) |
| Changes In Lease Liability | | (25.33) | 89.12 |
| Finance Cost | | (623.10) | (892.36) |
| Interest received | | 6.86 | 26.79 |
| Dividends paid to equity holders (including dividend distribution tax) | | (10,182.60) | (2,545.65) |
| Net cash flow from /(used In) financing activities | (C) | (15,641.21) | (7,566.17) |
| Net increase/(decrease) in cash and cash equivalents | (A+B+C) | 2,311.87 | (448.57) |
| Cash and cash equivalents as at the beginning of the year | | 709.14 | 1,157.68 |
| Effect of exchange differences on restatement on foreign currency cash & cash equivalents | | 0.04 | 0.03 |
| Cash and cash equivalents at the end of the year | | 3,021.04 | 709.14 |
| For Suven Pharmaceuticals Ltd | | | |
| Venkateswarlu Jasti | | | |
| Managing Director | | | |
| DIN: 00278028 | | | |
| Place : Hyderabad | | | |
| Date : 09th May 2022 | | | |

| SUVEN PHARMACEUTICALS LIMITED | | | |
|---|----------------|---|---|
| Consolidated Statement of Cash flows for the year ended 31st March, 2022 | | | |
| (All amounts in Indian Rupees In Lakhs, unless otherwise stated) | | | |
| Particulars | | For the year ended 31st March 2022 | For the year ended 31st March 2021 |
| A. Cash flow from operating activities | | | |
| Profit before tax | | 66,758.98 | 46,767.41 |
| Adjustments : | | | |
| Depreciation and amortisation expense | | 3,825.50 | 3,122.07 |
| Interest Income | | (6.86) | (26.79) |
| Finance Cost | | 623.10 | 914.37 |
| Gain on sale of Current Investment | | (820.31) | (332.77) |
| Debit balances writtenoff | | - | 72.16 |
| Effects of foreign exchange rates (Unrealized) | | 442.01 | (97.56) |
| Loss/(Profit) on disposal of Property, plant & equipment | | (0.06) | (3.36) |
| Operating profit before working capital changes | | 70,822.36 | 50,415.54 |
| Adjustments for (Increase)/decrease in operating assets | | | |
| Trade Receivables | | (13,608.80) | 1,336.08 |
| Inventories | | (8,233.69) | (2,620.82) |
| Other non current assets | | 26.97 | (78.95) |
| Other current assets | | (1,083.41) | (1,269.55) |
| Adjustments for Increase/(decrease) in operating liabilities | | | |
| Trade Payables | | 2,320.35 | 1,194.52 |
| Long term provisions | | 224.85 | (166.86) |
| Short term provision | | 44.86 | (102.78) |
| Other financial liabilities | | 548.66 | 655.53 |
| Other current liabilities | | 363.60 | (164.48) |
| Cash generated from operating activities | | 51,425.75 | 49,198.23 |
| Income taxes paid (net of refunds) | | (18,425.73) | (10,943.58) |
| Net Cash flows from operating activities | (A) | 33,000.02 | 38,254.65 |
| B. Cash flow from Investing activities | | | |
| Payments for Purchase of property, plant and equipment | | (7,518.67) | (11,084.60) |
| Proceeds from sale of Property, plant & equipment | | 0.06 | 3.36 |
| Changes in Investments | | 24,409.74 | (5,373.60) |
| Foreign currency translation reserve | | (484.39) | (0.27) |
| Fixed deposits/margin money-placed/matured | | (774.41) | (20.31) |
| Sale/(purchase) of mutual funds | | (29,242.55) | (14,659.28) |
| Bank balances not considered as cash and cash equivalents | | (10.47) | (5.12) |
| Net cash flow from /(used in) investing activities | (B) | (13,620.69) | (31,139.82) |
| C. Cash flows from financing activities | | | |
| (Repayment)/Proceeds from long term borrowings | | (959.73) | (5,472.65) |
| (Repayment)/Proceeds from short term borrowings | | (3,859.71) | 1,230.17 |
| Other non current financial assets | | (0.75) | (0.20) |
| Other current financial assets | | 3.15 | (1.39) |
| Changes In Lease Liability | | (25.33) | 89.12 |
| Finance Cost | | (623.10) | (892.36) |
| Interest received | | 6.86 | 26.79 |
| Dividends paid to equity holders (including dividend distribution) | | (10,182.60) | (2,545.65) |
| Net cash flow from /(used In) financing activities | (C) | (15,641.21) | (7,566.17) |
| Net increase/(decrease) in cash and cash equivalents | (A+B+C) | 3,738.12 | (451.33) |
| Cash and cash equivalents as at the beginning of the year | | 718.22 | 1,169.53 |
| Effect of exchange differences on restatement on foreign currency cash & cash equivalents | | 0.04 | 0.03 |
| Cash and cash equivalents at the end of the year | | 4,456.38 | 718.22 |
| For Suven Pharmaceuticals Ltd | | | |
| Venkateswarlu Jasti | | | |
| Managing Director | | | |
| DIN: 00278028 | | | |
| Place : Hyderabad | | | |
| Date : 09th May 2022 | | | |